Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.,European Journal of Gastroenterology & Hepatology

当前位置： X-MOL 学术 › Eur. Gastroenterol. Hepatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
European Journal of Gastroenterology & Hepatology ( IF 2.1 ) Pub Date : 2024-02-21 , DOI: 10.1097/meg.0000000000002728
Geert D’Haens ₁ , Filip Baert ₂ , Silvio Danese ₃ , Taku Kobayashi ₄ , Edward V. Loftus ₅ , William J. Sandborn ₆ , Quentin Dornic ₇ , Dirk Lindner ₇ , Krisztina Kisfalvi ₈ , Ed G. Marins ₈ , Séverine Vermeire ₉

Affiliation

Vedolizumab is an anti-α4β7 integrin antibody used to treat moderate to severe ulcerative colitis (UC) and Crohn's disease (CD). This post hoc analysis of patient-reported outcomes (PROs) from the VISIBLE 1 (NCT02611830) and 2 (NCT02611817) phase 3 studies evaluated onset of treatment effect on patient-reported symptoms during 6-week vedolizumab induction.

中文翻译：

维多珠单抗在溃疡性结肠炎和克罗恩病静脉诱导治疗期间的疗效：对 VISIBLE 1 和 2 研究中患者报告的结果进行事后分析。

Vedolizumab 是一种抗 α4β7 整合素抗体，用于治疗中度至重度溃疡性结肠炎 (UC) 和克罗恩病 (CD)。这项对 VISIBLE 1 (NCT02611830) 和 2 (NCT02611817) 3 期研究的患者报告结果 (PRO) 的事后分析评估了 6 周维多珠单抗诱导期间对患者报告症状的治疗效果。

更新日期：2024-02-21

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>